HIV Infections
Conditions
Brief summary
A randomized, placebo-controlled, once weekly dose for four weeks, double blind study in Healthy HIV-Uninfected Volunteers. Each of 3 consequent groups (120 mg, 200 mg and 280mg) enrolls 6 active and 2 placebo subjects.
Detailed description
The study aims to assess safety, tolerability and PK of once weekly administration of Elpida in different doses.
Interventions
DRUGElpida
elsulfavirine, capsules
DRUGplacebo
placebo
Sponsors
Viriom
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Double-blind study
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy males or females aged between 18-40 years. 2. Willing and able to complete all study procedures, visits and restrictions. 3. Capable of giving written informed consent. 4. Has been determined healthy by medical history, physical and vital signs examinations. 5. Has normal results for the following screening tests: complete blood count (CBC), sodium, potassium, blood urea nitrogen (BUN), serum creatinine, fasting blood sugar (FBS), creatine kinase, total calcium, cholesterol, triglyceride, total protein, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and urinalysis. 6. Females of reproductive potential (defined as women who have not been postmenopausal for at least 24 consecutive months \[i.e., who have had menses within the preceding 24 months\], or women who have not undergone surgical sterilization; specifically hysterectomy, salpingotomy, bilateral oophorectomy, and/or tubal ligation), must have a negative serum or urine pregnancy test with a sensitivity of at least 40 mIU/mL at Screening and prior to drug dosing on Day 1. 7. All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). If participating in sexual activity that could lead to pregnancy, the participant must agree to use two reliable methods of contraception simultaneously while receiving study treatment and for 6 months after stopping study drug. Subjects must either be abstinent or a combination of TWO of the following methods MUST be used appropriately: * Condoms (male or female) with or without a spermicidal agent; * Diaphragm or cervical cap with spermicide; * Intrauterine device (IUD); * Hormonal-based contraception. Participants who are not of reproductive potential (women who have been postmenopausal for at least 24 consecutive months or have undergone hysterectomy, salpingotomy, bilateral oophorectomy, and/or tubal ligation or men who have documented azoospermia) are eligible without requiring the use of contraceptives. Acceptable documentation of sterilization, menopause or male partner's azoospermia must be provided; serum follicle stimulating hormone (FSH) measurement can be used to document menopausal range.
Exclusion criteria
1. Hepatic or kidney disorders or any other disease or disorder which may in the opinion of the Investigator interfere with the results of the study or threaten the health of volunteers. 2. Clinically significant ECG abnormality according to ECG exam at Screening, subject's medical history or family history judged by the Investigator that the presence of, or an increased risk of cardiac abnormality. 3. Positive result for HIV, HCV or HBV at Screening. 4. Positive result for illicit drugs screen (opiates, amphetamines, cannabinoids or cocaine) or alcohol screen at Screening. 5. Active alcohol or and/or drug abuse that, in the opinion of the site investigator, would interfere with adherence to study requirements. 6. Received the excluded medications (as shown in Appendix 3) within 14 days or 28 days prior to the first dose of study drug, or within the 5 half-lives of individual medication, whichever is longer. 7. Participated in a clinical study and received any investigational drug or vaccine or medical device within 90 days prior to the first dose of study drug. 8. Pregnancy or breast feeding, male partners of pregnant females. Inability to understand the Protocol or follow its instructions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of AEs and SAEs | 36 days | Incidence of AEs and SAEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| elsulfavirine plasma concentration | 36 days | elsulfavirine plasma concentration |
| VM1500A plasma concentration | 36 days | active metabolite plasma concentration |
Countries
Thailand
Contacts
Primary ContactTapanee Mahasanprasert
Outcome results
None listed